Drugs in ATC Class L01ED

Up to Top Level ATC Classes

Up to L - Antineoplastic and immunomodulating agents

Up to L01 - ANTINEOPLASTIC AGENTS

Up to L01E - PROTEIN KINASE INHIBITORS

Drugs in ATC Class: L01ED - Anaplastic lymphoma kinase (ALK) inhibitors

Tradename	Generic Name
ALECENSA	alectinib hydrochloride
ALUNBRIG	brigatinib
XALKORI	crizotinib
ZYKADIA	ceritinib

L01ED Market Analysis and Financial Projection

The market for Anaplastic Lymphoma Kinase (ALK) inhibitors (ATC class L01ED) has undergone significant transformation, driven by evolving therapeutic advances and intellectual property dynamics. Here's an analysis of the market dynamics and patent landscape:

---

Market Dynamics

Growth Drivers

• Rising incidence of ALK-positive cancers: ALK inhibitors are primarily used in non-small cell lung cancer (NSCLC), which accounts for 85% of lung cancer cases[3][10]. Improved genomic testing has increased identification of ALK rearrangements, expanding the eligible patient pool[5][7].
• Pipeline innovation: Over 15 next-generation ALK inhibitors, including lorlatinib (3rd gen) and investigational drugs like NVL-655, target resistance mutations and improve CNS penetration[9][11]. The market is projected to grow from $1.5 billion in 2020 to $10.6 billion by 2030, at a 22% CAGR[3][10].
• Geographic expansion: The U.S. dominates sales (>30% market share), but Asia-Pacific is emerging due to rising cancer diagnoses and healthcare investments[12].

Competitive Landscape

• Key players: Pfizer (crizotinib), Roche (alectinib), Takeda (brigatinib), and Novartis (ceritinib) lead the market[5][12].
• Shift to next-gen therapies: Second- and third-generation inhibitors like alectinib and lorlatinib have surpassed first-gen drugs (e.g., crizotinib) as first-line treatments due to superior efficacy and CNS activity[11][12].

Challenges

• Drug resistance: Over 50% of patients develop resistance to first-line ALK inhibitors, necessitating costly next-gen therapies[9][11].
• High costs: Annual treatment costs for newer inhibitors exceed $100,000, limiting access in low-income regions[5][8].

---

Patent Landscape

Expired Patents and Generics

• Early ALK inhibitors, including crizotinib, faced patent expirations by the mid-2020s, enabling generic competition[1][8]. St. Jude’s foundational ALK patents expired, reducing licensing revenue and allowing generic production[1].
• Revenue impact: Licensing income from original patents totaled under $10 million net after expenses, with proceeds reinvested in research[1].

Active Patents and Extensions

• Later-generation drugs: Lorlatinib (approved in 2021) and entrectinib hold patents extending into the 2030s, with strategies like pediatric exclusivity adding 6–12 months of market protection[8][9].
• Legal strategies: Companies aggressively defend patents through litigation. For example, St. Jude enforced ALK patents against infringers, securing royalties until expiration[1].

Emerging Therapies

• NVL-655: Granted FDA Breakthrough Therapy Designation in 2024 for ALK-positive NSCLC resistant to existing inhibitors[5].
• Combination therapies: Trials explore ALK inhibitors with immune checkpoint inhibitors to address resistance[12].

---

Future Outlook

• Generics impact: Crizotinib generics are reducing costs but face competition from superior next-gen drugs[1][11].
• Innovation focus: Macrocyclic compounds and PROTAC-based degraders aim to overcome resistance, with 20+ agents in clinical trials[4][9].
• Market consolidation: The top 5 ALK inhibitors (crizotinib, ceritinib, alectinib, brigatinib, lorlatinib) control >90% of sales, but pipeline drugs like repotrectinib could disrupt the landscape[5][12].

---

“The race to develop ALK inhibitors reflects both the urgency of addressing resistance and the economic stakes in oncology markets.” – Industry Expert[12]

This rapidly evolving sector balances scientific innovation with complex IP strategies, aiming to sustain growth while improving patient access globally.

References

1. https://www.stjude.org/research/why-st-jude/shared-resources/technology-licensing/success-stories/st-jude-contribution-to-a-new-class-of-cancer-drugs.html
2. https://www.ntnu.no/ojs/index.php/norepid/article/view/4041/3728
3. https://www.prophecymarketinsights.com/market_insight/Global-Cancer-ALK-Inhibitor-Market-4665/market-size
4. https://pubmed.ncbi.nlm.nih.gov/37208827/
5. https://www.prnewswire.com/news-releases/alk-inhibitors-market-a-comprehensive-overview-of-current-trends-and-future-projections--delveinsight-302234916.html
6. https://bmjopen.bmj.com/content/13/3/e069645
7. https://www.thepharmaletter.com/pharmaceutical/alk-inhibitors-market-set-for-growth-driven-by-rising-cancer-cases
8. https://gabi-journal.net/overview-of-the-patent-expiry-of-non-tyrosine-kinase-inhibitors-approved-for-clinical-use-in-the-eu-and-usa.html
9. https://www.oaepublish.com/articles/cdr.2024.25
10. https://www.globenewswire.com/news-release/2021/04/16/2211697/0/en/Global-Cancer-ALK-Inhibitor-Market-is-estimated-to-be-US-10-6-billion-by-2030-with-a-CAGR-of-22-0-during-the-forecast-period-by-PMI.html
11. https://pcm.amegroups.org/article/view/5932/html
12. https://www.globenewswire.com/en/news-release/2021/04/21/2213884/28124/en/Insights-on-the-Anaplastic-Lymphoma-Kinase-ALK-Inhibitors-Global-Market-to-2026-Lorbrena-Overcomes-Xalkori-as-Front-Line-Therapy-in-NSCLC.html